Decoding Akeso's ASCO Plenary: A Guide to Interpreting Ivonescimab's Survival Data

Overview

The upcoming American Society of Clinical Oncology (ASCO) annual meeting has sparked intense interest around a specific late-stage trial: Akeso and Summit Therapeutics' investigational bispecific antibody, ivonescimab. This drug, targeting PD-1 and VEGF, has been awarded a coveted plenary session slot—a rare honor that typically signals practice-changing results. Wall Street analysts and oncology experts alike are speculating on what the survival data will show, especially in non-small cell lung cancer (NSCLC) where standard care (pembrolizumab) already sets a high bar. This tutorial will guide you through the key elements of understanding and evaluating such a high-profile disclosure, from trial design to regulatory implications.

Prerequisites

Before diving into the analysis, ensure you have a grounding in these concepts:

• Oncology trial endpoints: Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), hazard ratios (HR), and confidence intervals (CI).
• ASCO meeting structure: Plenary vs. oral vs. poster sessions, and what each implies about data quality.
• Bispecific antibody mechanisms: How simultaneous PD-1 and VEGF blockade might synergize.
• Non-small cell lung cancer (NSCLC) subtypes: Squamous vs. non-squamous, PD-L1 expression levels, and prior treatment lines.
• Biotech investment basics: How trial results affect stock valuations and partnership strategies (e.g., Akeso-Summit deal).

Familiarity with reading forest plots and Kaplan-Meier curves is helpful but not required.

Step-by-Step Guide to Analyzing the Ivonescimab Plenary Data

Step 1: Understand the Trial Context

Before the numbers are released, review the trial’s design. Ivonescimab is being evaluated in a Phase 3 study (e.g., HARMONi-A or similar) for first-line or second-line NSCLC. Key factors:

• Patient population: PD-L1 positive? EGFR wild-type? Prior therapies?
• Comparator arm: Chemotherapy alone, or an anti-PD-1 like pembrolizumab?
• Primary endpoint: Often PFS in lung cancer; secondary OS.

In the case of Akeso’s plenary, the excitement stems from early hints of an OS benefit, which is rare in first-line NSCLC. Check if the trial includes crossover (patients on control arm allowed to switch to ivonescimab after progression) – this can dilute OS signals.

Step 2: Examine the Hazard Ratios and Confidence Intervals

The core of survival analysis is the hazard ratio. An HR less than 1 favors ivonescimab. Pay attention to:

• Point estimate: e.g., HR = 0.70 means 30% reduction in risk of progression or death.
• 95% confidence interval: Should not cross 1.00. The narrower the interval, the more precise the estimate.
• P-value: Typically <0.05 for statistical significance, but regulatory filings require prespecified alpha control.

Example: If the plenary announces a PFS HR of 0.65 (95% CI 0.50–0.84, p<0.001), that is strong. But for OS, a modest HR of 0.80 might still be clinically meaningful if the CI stays below 1.00.

Step 3: Evaluate the Kaplan-Meier Curves

The curves tell the story over time. Look for:

• Early separation: Does ivonescimab start working sooner?
• Long tail: Are there durable responses beyond 12 months?
• Crossing lines: If curves cross early, it may indicate delayed benefit or harm.
• Number at risk: The table below the curves shows how many patients remain; if numbers drop sharply, the benefit may be limited.

A plenary presentation will include these visualizations, so watch for clear separation favoring the experimental arm.

Step 4: Assess Safety and Tolerability

Survival gains are worthless if toxicity is unacceptable. Review:

• Grade 3+ adverse events: Compare rates between arms. Immunotherapy combinations (PD-1 + VEGF) carry risks like hypertension, bleeding, and immune-related events.
• Treatment discontinuation: High dropout rates can skew efficacy data.
• Deaths on study: Any imbalance in fatal toxicities?

Ivonescimab’s safety profile in prior Phase 1/2 data showed manageable side effects, but size the Phase 3 numbers.

Step 5: Contextualize Against Standard of Care

Even if ivonescimab beats the control arm, it may not beat the current standard (e.g., pembrolizumab alone or with chemotherapy). Questions to ask:

• Was the control arm outdated? If chemotherapy alone, the benefit might be expected. But if the control was pembrolizumab, any added benefit is more impressive.
• What is the absolute improvement? A median PFS gain of 2 months might not justify the cost or toxicity.
• How does OS compare to historical data? Check IMpower150, KEYNOTE-189, etc.

A plenary slot often means the drug shows superiority over an active comparator, not just placebo.

Step 6: Consider Regulatory and Commercial Implications

Interpret the data through a business lens:

• FDA or EMA filing: Does the data support a new drug application? A plenary presentation can accelerate regulatory review.
• Partner dynamics: Summit Therapeutics (US rights) and Akeso (China) – how does the data affect their collaboration? Could it trigger milestone payments or a buyout?
• Market competition: How does ivonescimab compare to other bispecifics (e.g., Johnson & Johnson's amivantamab) or PD-1/VEGF combos?

Wall Street will model peak sales based on the magnitude of benefit and addressable patient population.

Common Mistakes When Interpreting Plenary Data

• Overinterpreting early trends: Plenary slots often highlight positive data, but read the full abstract for limitations. Survival curves may have short follow-up.
• Ignoring subgroup analyses: Be wary of cherry-picked subgroups (e.g., PD-L1 high) if the overall population missed significance.
• Confusing p-values with clinical relevance: A tiny p-value can occur with a trivial effect size if the trial is large enough. Always check the absolute difference.
• Assuming plenary equals approval: Many plenary drugs later fail regulatory hurdles due to toxicity, manufacturing, or data inconsistencies (e.g., promising Phase 2 data that doesn't hold in Phase 3).
• Disregarding the control arm quality: A weak comparator (e.g., old chemotherapy) overstates results. Compare to current best practice.
• Believing the hype: Stock surges often precede plenary talks, but reality may disappoint. Wait for peer-reviewed publication.

Summary

Akeso’s plenary spot at ASCO for ivonescimab in lung cancer signals potentially important survival data. To evaluate it, focus on the trial design (comparator, endpoints), hazard ratios with confidence intervals, Kaplan-Meier curves, safety profile, and real-world context. Avoid common pitfalls like cherry-picking subgroups or equating statistical significance with clinical value. Ultimately, the plenary presentation is a starting point—not a final verdict—for understanding whether ivonescimab can challenge existing therapies. Stay tuned for the full data release to make informed assessments.